About - ONCY :

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Employees - 28, CEO - Wayne F. Pisano, Sector - Healthcare, Country - CA, Market Cap -

Altman ZScore(max is 10): -36.09, Piotroski Score(max is 10): 1, Working Capital: $12719000, Total Assets: $19702000, Retained Earnings: $-484400000, EBIT: -33255000, Total Liabilities: $13208000, Revenue: $0

AryaFin Target Price - $0.14 - Current Price $ - Analyst Target Price $

Stats & Key Metrics
TickerONCY
Index
Curent Price
Change
Market Cap
Average Volume
Income
Sales
Book Value/Share
Cash/Share
Dividend Est
Dividend TTM
Dividend Ex-Date
Employees
Moving Avg 20days
Moving Avg 50days
Moving Avg 200days
Shares Outstanding
Earnings Date
Inst. Ownership
Key Ratios & Margins
Price/Earnings
Forwad P/E
PE Growth
Price/Sales
Price/Book
Price/Cash
Price/FCF
Quick Ratio
Current Ratio
Debt/Equity
Return on Assets
Return on Equity
Return on Investment
Gross Margin
Ops Margin
Profit Margin
RSI
BETA(β)
From 52week Low
From 52week High
Earnings & Valuation
EPS
EPS next Year
EPS next Qtr
EPS this Year
EPS next 5 Year
EPS past 5 Year
Sales past 5 Year
EPS Y/Y
Sales Y/Y
EPS Q/Q
Sales Q/Q
Sales Surprise
EPS Surprise
ATR(14)
Perf Week
Perf Month
Perf Quarter
Perf Year
Perf YTD
Target Price

AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer